Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

Corvus Pharmaceuticals maintains a “Strong Buy” rating, driven by advancing soquelitinib in relapsed/refractory PTCL and moderate-to-severe atopic dermatitis [AD]. The company anticipates a pivotal interim futility analysis for its phase 3 PTCL trial in Q1 2027, representing a major inflection point.

Positive phase 1 AD data and the initiation of the phase 2 SIERRA1 study, with topline results expected in Q3 2027, reinforce the pipeline’s potential.

With $215.2M in cash, the company is funded into Q2 2028, minimizing near-term dilution risk and supporting ongoing clinical development.